P108 Development and evaluation of the i-Tracker Risankizumab and i-Tracker Anti-Risankizumab kits: rapid and innovative tests intended for monitoring patients treated with Risankizumab

Abstract Background Risankizumab is a human monoclonal antibody directed against the cytokine IL-23. This drug commonly used for treatment of patients with chronic inflammatory diseases such as psoriasis. about to get an indication in Crohn's disease and Ulcerative Colitis. Theradiag has just developed new rapid (results less than 40 minutes) innovative assays allowing quantification Risankizumab: these tests are available on i-Track10 chemiluminescence platform well anti-Risankizumab antibodies induced by patient. Methods The analytical performance was studied using two types samples: serum samples spiked or antibodies, from treated Risankizumab. For assay, captured IL-23-coupled magnetic microparticles detected acridinium ester-conjugated polyclonal antibody. assay coupled were used. thus conjugated ester. Light emission ester conjugates directly related amount present sample. Results i-Tracker kit shows very good accuracy (the percentages recovery between 84% 108%). intra-test inter-test reproducibility (CV <7.3% CV <8.0% assay). No interference biological agents (bilirubin, hemoglobin, triglycerides, rheumatoid factors) detected. measurement ranges 1 µg/mL 80 10 ng/mL 2000 antibodies. Conclusion kits obtained highly accurate. Monitoring plasma levels could provide clinicians relevant information improve efficacy.